← Research library

Ventvil Phase I injection safety trial registration (HEP-VTL-01)

Planned study · 2017

Registered population or design
52 healthy volunteers listed in the registration. An analyzed sample and arm sizes are unavailable.
Results availability
The Phase I registration lists 52 healthy volunteers and describes a double-blind placebo-controlled study of injection safety and tolerability. Clinical results remain unavailable.

Study data at a glance

Participants or experimental model
52 healthy volunteers listed in the registration. An analyzed sample and arm sizes are unavailable.
Dose, route and schedule
Double-blind randomized placebo comparison of escalating single and repeat intramuscular doses. Dose levels and allocation are unavailable in the public entry.
Registered study design
The Phase I registration lists 52 healthy volunteers and describes a double-blind placebo-controlled study of injection safety and tolerability. Clinical results remain unavailable.

Protocol source ↗ · Registry entry for HEP-VTL-01

Study limitations and source details

Study limitations

  • The public record lists the study as completed and supplies no group-level safety results or verified analyzed denominator.

Source details

Clinical trial registration

Registry entry and contemporary sponsor announcement

Sources checked

Added to the library

Citation

Trial protocol / registrationFull text available

SIA Peptides (sponsor). Ventvil Phase I injection safety trial registration (HEP-VTL-01) Russian clinical-trial register mirror. Authorization No. 581, 3 November 2017

Study source ↗ · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards